Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25

5 Nov 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

CNBC's "Fast Money" - Episode Summary (November 5, 2025)

Episode Overview Title: Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations Description: The episode discusses recent earnings reports indicating contrasting consumer spending trends and highlights ongoing negotiations between the White House and pharmaceutical companies regarding obesity drug pricing.

---

Key Themes and Discussions

  1. Diverging Consumer Trends
  2. K-Shaped Recovery: The episode highlights a K-shaped recovery in the consumer economy, where different segments of consumers are experiencing varying levels of economic stress.
  3. Earnings Reports:
  4. McDonald's: Despite missing earnings estimates, reported increased same-store sales. However, the CEO noted a significant drop in traffic from lower-income consumers.
  5. Chipotle and Cava: Similar cautious outlook reflecting challenges in attracting younger, cash-strapped consumers.
  6. Contrasting Reports:
  7. DoorDash and Elf Beauty: Pressure on lower-end consumer segments.
  8. Shopify and Uber: Positive commentary suggesting a robust consumer base.
  1. Future Consumer Insights
  2. Upcoming earnings reports from Ralph Lauren, Tapestry, Target, and Walmart will further clarify consumer spending trends.
  3. Economic Indicators: Concerns about inflation, SNAP benefits, and mortgage rates affecting consumer behavior.
  1. Impacts on Retail
  2. Retailers Responding to Pressure: Heavy discounting expected as retailers prepare for the holiday season, potentially impacting profit margins.
  3. Stock Performances: Retail stocks like Walmart and Costco positioned to benefit from consumers trading down.
  1. Pharmaceutical Price Negotiations
  2. Drug Pricing Talks:
  3. Novo Nordisk and Eli Lilly nearing agreements with the White House for lower prices on weight-loss drugs.
  4. Potential changes in Medicare coverage for these drugs, moving from diabetes treatment to obesity treatment.
  5. Market Implications:
  6. The significance of obtaining Medicare coverage is emphasized as a key factor for the future success of these pharmaceuticals.
  7. The impact of such agreements on stock prices of both companies is discussed, with Novo Nordisk facing challenges due to recent cuts in guidance.
  1. Supreme Court Discussions
  2. Tariff Legalities: Oral arguments regarding the legality of tariffs imposed by the Trump administration, with implications for revenue and business operations across various sectors.

---

Key Takeaways

  • Consumer Behavior is Polarized: The divide between affluent consumers and those facing financial stress is evident in earnings reports across sectors.
  • Pharmaceutical Landscape is Shifting: Pricing negotiations may reshape how obesity drugs are marketed and covered, influencing the competitive landscape between major companies.
  • Retail Outlook is Cautious: Retailers are bracing for a challenging holiday season amidst economic uncertainties, with a focus on discount strategies to attract cost-conscious consumers.

---

Conclusion The episode presents a nuanced view of the current economic landscape, illustrating the complexities of consumer behavior and pharmaceutical market dynamics. The discussions underscore the importance of upcoming earnings reports and negotiations that could significantly impact investor sentiment and market trends.

Additional Information For more insights and updates, visit [Fast Money on CNBC](http://fastmoney.cnbc.com).

---

Disclaimer: The opinions expressed by participants in this episode are their own and do not reflect the views of CNBC or its affiliates.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:02Live from the Nasdaq market site in the heart of New York City's Times Square this is fast money Here's what's on tap tonight. A tale of two consumers. What results from McDonald's and a slew of other companies tell us about where people are spending and where they're not? And nearing a deal, the White House set to announce lower prices on the most popular weight loss drugs. What it'll mean for the makers as the divergence between Lilly and Novo grows wider and wider. Plus, from Qualcomm to Snap to Elf Beauty and more, we are dissecting another big night of earnings. Terrace takes center stage at the Supreme Court.

0:31And is it time to buy Roku? The chart masters here who lay out the case for the streamer. I'm Melissa Lee. Come to you live from Studio B at the NASDAQ. On the desk tonight, Steve Grasso, Carter Worth, Dan Nathan, and Diadami. We start off with the latest signs. A K-shaped consumer economy is forming. McDonald's rising despite missing Wall Street earnings estimates before the bell. The fast food giant did see an increase in same-store sales, but commentary on the call was very cautious. CO Chris Kamsinski saying low-end consumer traffic declined by double digits in the quarter, adding that he expects pressure to continue in the next year.

1:03That sentiment echoed by Chipotle in its report last week and Cava just yesterday, both saying their core consumer base, which skews younger and more cash strapped, just isn't showing up. Outside of restaurants, after hours moves in DoorDash and Elf Beauty suggest similar pressure on those companies' client base. But commentary from Uber and Shopify paints a very different picture. Shopify saying their consumer can't get enough, while Uber seems to see blue skies ahead for business firing on all cylinders. We'll get more reads on the consumer in coming weeks. Ralph Lauren, Tapestry, Target and Walmart all still to come this month.

1:35So what is the real read on the consumer? Guy, what's your take? Exactly that, that there's two different economies right now. The people that are doing well that are trading down but are still a bit have the ability to spend. And then on the lower end, people are strapped. And I think that's been going on for quite some time. And we see it in the performances of these stocks. I mean, Walmart, I think, tells the story. I think McDonald's, to a certain extent, tells the story. They'll need to get that one above$325. On the other end of the coin, if you're in the dollar stores, that's been a rough slog over the last couple of years.

2:06And if you're in the middle, you're absolutely nowhere. So this, to me, just reinforces everything I've thought for a while. 30 % of U.S. transactions at McDonald's were the extra value meals, which is interesting. And they're also saying that the uncertainty surrounding SNAP benefits are going to put further pressure on those consumers who are already struggling. Yeah, that's a difficult situation. So hopefully that resolves itself. New York Times, The Daily had a podcast yesterday going into a rural county in West Virginia, talking to folks and go check that out. It's really sad. Hopefully they get that sorted out.

2:39But, you know, one thing, again, to the K shape on the higher end, there's not it's not all roses. Look at Live Nation today, which obviously owns Ticketmaster's down 10 percent after their results. They missed on earnings. The revenues came in line. That stock is down 25 percent from an all time high just a few weeks ago. And, you know, so it really is, you know, some of the stuff experiences. That was the big story after we got done with all the goods during the pandemic. And it seems like some of that is coming unwound a little bit. So, again, you know, you tell me what inflation is going to do.

3:10You tell me what the course of the Fed is going to do. We've talked to plenty of folks over the last few weeks or so that they don't see 30 year mortgage rates going below 6 percent. So the housing market is still pretty well locked. And then you extend that a bit further. You saw this company, Trex, that makes decks, you know, and that thing was down, I don't know, 25 percent or something like that today. Home Depot was down in sympathy. So I think you've got to start broadening it out a little bit. You're going to continue to see heavy discounting into the holiday season. If you look at some of those, whether it's Guys Dicks or Best Buy or one of those sorts of names that are obviously right there for holiday season.

3:44But you're also going to see, I think, some pressure on margins because of that, you know, promotional environment. I like the existing home sales, one that Dan just touched on. He talked about mortgage rates. If you're trapped in your home, you can't get the money out of your home. That's a huge thing. And if mortgage rates do not come down, people wind up being house rich, cash poor. But to Guy's point, Delta is for the first time ever selling more first or should be on the precipice of selling more first class tickets than coach. First time ever. That was a staggering stat that jumped out at me.

4:22Coke, selling more premium. So it's fair life, smart orders. Apple, selling more phones. Walmart and Target, you have that trade down element. Costco, affluent are bundling up, buying a bulk. And others are just stretching it out, making their groceries last. So we're trading down, we're eating at home. No one's eating out. So it all makes total sense. It's a bifurcated market, and it probably continues until further notice. That's the word, right? So a K-shaped, I mean, that's kitsch. K-shaped, I mean, what does that mean? Somebody made that up because it felt good. They put it in a big research report, and everyone bid on it.

5:01Bifurcation is a word that's in the English language for a long time. We have a bifurcated market, as is the case. So it's not just the affluent. Think about a Capri. They have Versace. And Jimmy Choo and Michael Coors, that stock is at a 10-year low. Versus William Sonoma, very expensive. Bachelors, that's up at the high. Ralph Lauren, up at the high. But it's not Hermes and LVMH struggling. Estee Lauder's struggling. So it's not so much what type of consumer. It really is idiosyncratic. There are, generally speaking, problems with the consumer. We know that restaurants are almost universally under trouble.

5:31Housing stocks, not doing great. Autos, really mixed, and it goes on and on. Yeah. And the issue in terms of the higher-end consumer households above $100 ,000 is that we're now starting to hear about the layoffs that are existing in the corporate office. So not just the frontline workers, but those sitting in the offices, middle management, et cetera. And who are those people? Those people have been the ones who are spending. And now there's a threat of their jobs. So what does the economy look like then? Well, that's exactly right. And listen, Walmart was way ahead of this a couple of years ago when we started hearing 65 percent of their customer base earned more than$100 ,000.

6:06That number has gone up. Now, people will say, well, you know what, guy,$100 ,000 isn't what it was five, six years ago. I understand that. But the point is, there's been a trade down at the higher end without question. And that's going to continue. Who's set up best to take advantage of that? Steve just mentioned Costco. Absolutely. Walmart. Yes. Even McDonald's, to a certain extent, I believe, is set up to take advantage of that. Yeah. You know, and on the kitschy K-shape sort of thing, Torsten Slack from Apollo had a note out this morning. He was talking about actually it's a K-shape for corporations, too.

6:35He was looking at the S &P 500. We know the story. You You know, if you look at the MAG-7, earnings have been going up all year for them. For the 493, they've been going down, right? And it really speaks to all these names. We didn't even mention a MAG-7 name. We're talking about the others here. So if their consumers are having a hard time, you likely think that the companies are having a hard time because they're also trying to process all these tariffs. You know, go back six, seven months, whatever it was, it was a doomsday scenario because these tariffs are a tax on consumers or the companies have to eat it.

7:03Well, we've done okay in that regard, maybe until now. You know, maybe it is a cumulative sort of effect one way or another. So I just think it's interesting that we're also seeing a case shape for S &P earnings, too. Right. But in terms of the ones that you buy, though, I mean, if you take a look at Walmart, do you buy Walmart at a forward P.E. that is higher than Alphabet? I think so. You do? Well, yeah, and we've said that for, listen, I believe, I understand why people would say absolutely not. Valuation doesn't make sense. By the way, as Tim said last night about a stock, that's been true for quite some time.

7:33So I think you sort of throw valuation to the side, especially given the fact that I believe Walmart is winning in terms of utilizing AI and improving their margins. So Walmart specifically, yes, I think you can pay up for the stock. Yeah, and I think you go to Costco as well. So we would round tripping this one. Same type of it's underperformed Walmart by about 10 percentage points year to date. But the the the membership is sticky. So people continue. It's above 90 percent renewal rate and people buy in bulk. and you avoid that tariff by buying in bulk, and you avoid that inflation because you spread it out a little bit thicker.

8:09Well, they have been able to avoid tariffs because of their product mix. They can always change their product mix to sort of work around the tariff situation, which has been an advantage of Costco. In terms of the charts, Carter, do these charts look strong? Well, Walmart and Costco have also diverged, but a bifurcation there. Walmart's the better of the two. But just in terms of, let's just talk about the sector overall. Well, since Labor Day, the S &P 500 consumer discretionary sector is up some 7%. The equal-weighted sector is down 7%. And that is simply a function of two big stocks, Amazon and Tesla, representing 45 % of the weight of the sector.

8:44So the equal-weighted consumer discretionary sector itself is the true message of that area of the market. For more on the State of the Consumer, Tanger CEO and President Stephen Yaloff is with us here on set. Tanger reported earnings yesterday. Stephen, great to have you with us. Thanks for having me back. Um, record leasing volume. So you're seeing just brisk demand for retail space or sort of challenges, but we're talking about in terms of a bifurcated economy in some pockets of the consumer facing problems right now. Well, you know, it's interesting to sit and listen to what you were just talking about in the state of the consumer and where they're trading up and where they're sort of avoiding.

9:21And, you know, a lot of the brands that we're doing business with are many of the brands that you're talking about. What's interesting is they haven't taken their foot off the gas pedal with regard to growing their business and finding new locations. I think we're seeing some of the benefits of that. When a tenant finds space, what sort of time frame are they looking at in the future? I mean, they're saying the next year we're going to expect all the traffic to be here, or is it more like a five-year play? Yeah, no, I think the retailers are really about a year out. So right now we already have all of it.

9:50The rest of our 25s obviously are baked. 26s, we're probably about three-quarters of the way done. and now we're doing deals for late 26 and 27. Stephen, you're winning on the experiential side. You talked about that last time, but what you're also winning too is value has become more important than tariffs. And you guys, you and your occupants win to that in terms of the customer base that you serve. Well, I think particularly in the outlet channel, I think that value conversation is really important. And I heard a lot of you talk about that today, whether it's the restaurants that you choose to eat at or the stores that you choose to shop.

10:22And for us, you know, being on sale every day is a really powerful message to the consumer, especially now. Has your demographics changed at all in terms of who you're seeing show up? Well, yeah, you know, that younger consumer, you know, I listened to the Kava report and the Chipotle report. And one of the things that I thought was really interesting, particularly the CEO of Kava said this morning, is that the products are priced below inflation, which they think is doing a great job of getting them, a younger consumer, to come and convert with them when they choose to go to that store. You know, interesting in the outlet space, I think we find that our brands are almost deflationary in that the brand pricing is actually with the markdown.

11:02You also find it probably below that cost of inflation. How are you forecasting the retail, the holiday season for retailers? And what sorts of metrics are you looking at? What's on your dashboard in terms of indicating to you that the consumer will continue to spend through December? Well, the things that we're looking at from a retailer's perspective is stock and staff. You know, if you see the retailers are thinking that they're not going to have as much staff in the store, that's a problem. And the same thing with inventory. If there's no inventory in the store, that's a bigger problem because you can't sell what's not in the store.

11:32But we're seeing the stores are stocked. The stores are well staffed. We're really optimistic. In fact, you know, with government shutdown the month of October, we saw a traffic build in the month of October. So as counterintuitive as that might sound, I think people are looking to come to our centers. They're looking to shop value. They know they've got to buy holiday gift giving. I think the National Retail Federation is still saying that there's going to be an increase in spending this year versus last year. And we haven't seen any signs of slowdown yet. So, Stephen, you have a higher occupancy rate than your competition.

12:04Are you using analytics or using AI? Like, how are you deciding out who's going into those stores? How has it changed in the last five years? Yeah, you know, over the last five years, I think we're letting the customer, we're speaking to the customer a little bit more. We're listening to where the brands that they want to shop. Look, bringing brands into a shop is when you own a shopping center, you have to merchandise that center. You're like the general merchandise manager of an old department store that's looking for great brands that are going to bring the traffic in, but also bring the other brands in.

12:31So we're making merchandising decisions. Let's take Lululemon or Sephora, really important brands from a consumer traffic generation point of view, but equally important when we're talking to other brands and saying this is a property that you want to be in. They're going to ask who the other retailers. And when you mention some of those higher end names and brands that are really hot right now, that's who the consumer is looking for. That's who the other retailer is looking for. Question on Nike. Obviously, that's a very big tenant, if not one of your biggest. Any thoughts? Because the whole shoe space is struggling.

13:03Do you see any change in trend there from some of the smaller operators? But also you see the struggle in Adidas. But Nike in particular is the big one. Yeah. You know, I think full price Nike because they're so distributed. I think we're going to see a lot of problems, you know, in some in some sectors, but not necessarily in other sectors. And all sales might be off in, you know, in our portfolio. We're still finding that that consumer is looking for, again, brands that they want. You know, our consumer is not coming in looking for commodity. They're not looking for a pair of sneakers at the best possible price.

13:36They want Nikes, and they want Nikes at the best price. And as we talk about trading down or the top of the K, you know, we see an aspirational customer that wants to buy into brand. We're also seeing a higher end customer who's like, why pay the most for a pair of sneakers? If I want Nikes, I'm going to go shop them in the most value offer that I can find. Unrivaled sports partnership deal that you, I think it was just announced. Speak to that because it's fascinating. Yeah, you know, so as an owner and operator of outlet shopping centers, I think what's really important and what folks might not know is it's really incumbent on us as the operator to drive traffic into our shopping centers.

14:13A lot of the brands in an outlet center are not using their marketing capital to say, hey, go shop my off price channel. They're using their money to say, hey, go shop my full price channel. So it's really as it becomes more important for us to drive traffic, we're looking for new and organic ways to bring people into our centers. Unrivaled Sports is the biggest name in youth athletics and experiences. And essentially what it is, I'm sure all you guys have attended one of these venues where your kids have a game or a tournament on the travel team that they're in. Well, they host these travel team events.

14:49and because they're so proximate to our shopping centers, our partnership with them allows us to share their experiences and also be on the itinerary of every youth athlete and their families that comes to one of those venues. That's a lot of people. Steven, great to see you. Thanks for stopping by. I appreciate it. Thanks for having me back. Steven Yellof, Tanger. Do you see this as an outlier in terms of record-facing volume and the traffic that that's not the real tell on the overall economy? This guy's as good as the cats, by the way. And that's not a dispute. But it's an interesting read, right?

15:23We can sit here and go back and forth for every one of this. There's another one of that. Like we were talking about Instacart. That's your maple bear. You know, that thing has traded so poorly for the last couple months. And now all of a sudden DoorDash is catching up to it. DoorDash is down 30%, right? So that's the hard part. That's why we kind of diagnose these names and look at these situations every day. But it's really hard to look at it as a mosaic right now and say, like, this is what the consumer is doing because that's pretty strong. T.J. Maxx, we always say, pretty strong, you know, that sort of thing.

15:53And, you know, we're even starting to see some of these, you know, you mentioned Macy's early today. That thing is starting to pick its head up a little bit. So I don't know. It's about as clear as mud, Mel. Yeah. I mean, Carter mentioned Tapestry versus Williams-Sonoma. Very different stories. Sort of the same kind of demographic. 100%. But to go back, I mean, they're just a great operator. If you look at the quarter, I mean, they're really operating at a high level. And they're trying to figure out how do you drive traffic. Stephen just spoke to that. So stocks had a decent little run since April.

16:20Like many stocks have, I still think there's room to the upside. You have back to school. You have Halloween. Then you have pre-holiday sales. They're always discounted sales when you look at a tanger, sometimes as much as 50 % or 60 % off. It's experiential when you go to these outlet centers. I like them into the holiday season. You know, speaking of a great operator, in the financial crisis, the REIT space, the sector went down about 78 percent. Tanger went down only 40. And they have always exhibited a relative period of strength when things are really bad. An earnings alert here on SnapShare, the social media company jumping after topping revenue estimates.

16:56Julia Borson's got all the details. Hey, Julia. Hey, Melissa. SnapShare is soaring now about 26 percent on a revenue beat, stronger daily active user growth, unexpected plus guidance to fourth quarter earnings well ahead of estimates. The company announced a$500 million stock repurchase program and a partnership with Perplexity to bring its AI chatbot into Snapchat. Perplexity is paying$400 million over the course of a year. Snap saying, quote, our investments in AI and machine learning are delivering measurable gains for advertisers. Going on to say purchase-related ad revenue grew over 30 percent year over year, reflecting higher attribution accuracy and better campaign performance.

17:37The company did warn that engagement could decline as they roll out new products and daily active users may decline in the fourth quarter as new age verification and age limit laws go into effect. But they say they're working to improve average revenue per user as well as to improve financial efficiency. Melissa? Julia, thanks. Julia Worsten. I want to go to Dan. I feel like you've traded this in the past pretty well. This is one I kind of thought about, man, it's just so washed out and there's just nothing really going on. I know Evan Spiegel's been telling a story about, you know, AR, VR. They have some new devices they're about to launch here.

18:12But the stock honestly has not been able to get out of its own way while the stock market's been soaring. This is the sort of deal, though, for a company like this that will give you a bit of hope. It looks like, you know, Google paying Apple sort of thing. It's also a scenario where, you know, they have not been spending whatever the number is. This is a$6.5 billion revenue company, so$400 million in a year. That's not insignificant by any means, but they haven't spent billions of dollars building out their own LLM, that sort of thing. And I think that's going to be a story going forward. I think you're going to see this stuff a bit commoditized, and these companies with the models are going to start paying people to use their service.

18:48$500 million stock buyback is not insignificant in a company this size, and their free cash flow almost doubled what the street was looking for. It's hard to chase this stock up or down, but this is actually one of the better quarters we've seen in a while. This is obviously a massive gap higher, Carter. So, yeah, I mean, you know, you referred to how bad this has been. It was IPOs back in 17. I think it's below its IPO price. I mean, OK, maybe for a trade, but I'm with this. No chasing. You know, when you look at price targets, it's right at price targets right now. So I would not chase it. Give it a three day.

19:19We'll see where it's settling. Coming up more after hours action to bring you with Qualcomm, Lyft, Robinhood and more. We're all reporting results in just the last hour. The details and the numbers in the quarters next. Plus shares of Novo Nordisk lower on its own results. What spooking investors and where Novo and Eli Lilly stand on drug price negotiations. Do not go anywhere. Fast Money is back in two.

19:41This is Fast Money with Melissa Lee. Right here on CNBC.

19:54Welcome back to Fast Money. The Supreme Court today hearing oral arguments on the legality of some of President Trump's tariffs. At issue, the president's use of an emergency law to justify the levies. Eamon Javers has got the details on this. Eamon. Yeah, Melissa, this was an interesting one today. High stakes, obviously,$90 billion in already collected tariff revenue is on the line. What the administration was arguing through the person of John Sauer, he's the Solicitor General, was that this law from 1977, IEPA, does give the president the authority to impose tariffs, even though the law itself doesn't say the word tariffs anywhere in it.

20:31Here's what he said. Congress is a practical matter. Can't get this power back once it's handed it over to the president. It's a one-way ratchet toward the gradual but continual accretion of power in the executive branch and away from the people's elected representatives. Sorry, that was actually Neil Gorsuch, the Supreme Court justice. And what you heard from him just there, Melissa, is important, because that's what raised everybody's eyebrows today, was that you had some of the justices who would be expected to maybe politically, ideologically, and for all the other reasons, side with the Trump administration.

21:09But even those justices were expressing some real skepticism here about the Trump administration's case. Because that law does not mention tariffs, because the tariff power and taxation power is inherent to Congress in the Constitution, and because they're worried about this idea of Congress just ceding huge amounts of authority to the executive branch, all of that sort of ends up with this package where you get some conservatives who are very skeptical. So what's going to happen now? The justices are going to take all this back into their chambers. They're going to give it a think. And then at some point, and we don't know when, we are going to get a ruling from the Supreme Court.

Read the full transcript

21:45And the pressure is on because of that$90 billion figure I told you about at the top. That's the amount of money that the Treasury would have to pay back to companies if the ruling goes against the administration. There are other ways for this administration to impose tariffs in the future, but that revenue was collected under the old authority. They'd have to write a check. And one of the big questions I think now is who would get the largest check? Who are the largest tariff payers in America right now? How many of them are publicly traded? And for which of them would that check be big enough to be material to their stock price?

22:19Right. Eamon, thank you. Eamon Javers. What we did see in today's session, that was a reaction amongst a lot of the retailers, which had been hardest hit when the tariffs first went into effect. So we saw names like a Macy's, for instance, up a lot, Target up a lot. And so you have to connect the dots here in terms of if it was a negative for these guys when they were slapped on, because you always slap tariffs, George Korn says, slap the tariffs on them, then it should be a positive in theory. In theory, absolutely. In theory. There's a lot of chapters left in this, but if you want to try to game this out, I mean, if you want to play the continued bounce in some of these names on the back of that, as Dan would say, have at it, I think that's a very different difficult game to play.

23:03I'll say this, target, any bounce in target to me is a selling opportunity. I think they still are under considerable pressure. Yeah, but on a macro level, if you think about this, if those revenues are leaving the government and they're going back and we're in this inflationary environment and we have a government shutdown, all of that doesn't make for a great backdrop for the economy right here and right now. We just spent 10 minutes talking about a consumer that's kind of strapped. We talked about 493 stocks in the S &P 500 where earnings are not growing. So, you know, you would think that this would give a bit more clarity for a lot of companies, and it certainly will.

23:36But a lot of these companies have actually learned to live with these parameters. So, again, I think for the macro, it's not particularly an easy situation either. The flip side, in terms of the impact on the U.S. government, they've got to write the checks. So that's$90 billion going out of Treasury to someplace else. That's a whole. If this winds up weakening the economy, which I would think that it would, everyone would agree that then I fast forward to cuts. I think Powell's got a cut then, right? So it's more likely that he cuts and gets back on to more systemic cuts versus skipping. So it weakens the economy because Treasury's writing the check.

24:11But it could help the private sector because the tariffs are lifted. It could, but I don't know where that money goes back to. So does it go back to the retailers or does the consumer get the check? No, I don't think the consumer's getting anything. So don't you think that, I don't know if it has to go back, quite honestly. The Supreme Court could rule against, which I think they will. I think they'll rule against it. And then that money, they could say whatever you've collected thus far, you keep. And now going forward, you don't. Because it's too messy. It's too messy going back. You'd say, okay, that was bad, but go forward.

24:46It's like putting the toothpaste back in the tube. Or some such metaphor. Coming up, more after hours action. Qualcomm, Lift, Robin Hood, among the names reporting results in the last hour. The details and numbers in the quarter is next. You're watching Fast Money Live from the Nasdaq Market Side in Times Square. Back right after this.

25:14Welcome back to Fast Money and Earnings Alert on Qualcomm. Shares dropping in extended trading despite the company beating revenue and earnings expectations and giving strong guidance. Last week, Qualcomm said it was entering the AI race with the new accelerator chip competing with the likes of NVIDIA and AMD. Shares rose 11 percent on that news. It is now down 3 percent plus in the after-hour session. Guy, what do you make of this one? I mean, I think it's funny. I thought the quarter's fine and the guide was fine. So it's hard to figure out because if you just look at this on valuation alone, I mean, this is fine.

25:44So basically, the stock in the after-hours has given up what it got during the day, which it zeroes out. But forget about all the deals we just heard. If you want to put in a value in this space, I think Qualcomm still makes sense. Good day for semiconductors, though, during the regular session. Well, until the last, I don't know what you want to call it, half an hour for NVIDIA, it sold off a few percent. It was interesting because the FT kind of book, you know, that's that newspaper that's the Financial Times. Salmon, is that what you call it? The Salmon newspaper? Salmon. Salmon. They kind of bookended the day with some NVIDIA stuff or just really some AI stuff that started out this morning, an article talking about Chinese subsidies for energy and really trying to encourage their companies to kind of continue to move.

26:24And I really thought about it as these are all, you know, incentives to kind of move away from NVIDIA and CUDA and really kind of innovate on their own. And then in the last, what, half an hour of the day, there was an article that came out from the FT where Jensen Wong is at a conference and he said the Chinese are going to win and we are being cynical and they are being optimistic. And again, he's speaking to an audience of one in that regard, but it was just kind of interesting that that took the stock down at the end of the day. Yeah. You know, when you look at them against NVIDIA, they pale drastically in comparison.

26:54But when you look at what they do have, 12 ,600 patents. They get royalties from 1 ,000 different device models. They have$8 billion in free cash flow. They're the leader in 5G. I see a buy weakness in the stock. All right. What do you say? What does the chart say? A pair of twos. A pair of twos. I was more stuck on it. Is it salmon or is it coral? I think coral's stronger. I think salmon's lighter. But either way, it's the only one that's got a color. It's true. Yeah, it's true. The only one. Coming up. The next move in the weight loss drug space is Novo Nordisk and Eli Lilly near a deal to cut prices.

27:29The latest on those negotiations when Fast Money returns.

27:38Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back. Right after this.

27:54Welcome back to Fast Money Stocks. Bouncing back from yesterday's losses, the Dow jumping 225 points, the S &P up about four-tenths of a percent, and the Nasdaq climbing nearly seven-tenths of a percent. Shares of Deccan Company Trex dropping more than 30 percent after missing earnings expectations last night, giving disappointing guidance for the rest of the year. The company's seeing weakness in the repair and remodel sector and reduced home improvement spending. And more after hours action here. Robinhood topping expectations on the top and bottom line. Arm Holdings doing the same and hiking Q3 guidance.

28:22And Lyft posting a slight miss on revenue estimates. DoorDash, meantime, dropping after missing EPS expectations. And Elf Beauty also falling as revenues come in lighter than expected. Well, the battle for MetSaras heating up even further. The Wall Street Journal reporting just in the last hour that Pfizer is preparing to make yet another bid for the obesity biotech coming on the heels of a fresh offer by Novo Nordisk, valued at roughly$10 billion. Midsara moving higher in extended trading. Novo had been down as much as 4 % in the regular session after disappointing third quarter results and a cut to its full year guidance for the fourth time this year.

28:57For more on all of this, let's bring in BMO, head of health care research, Evan David Siegerman. Evan, great to have you with us. Thank you for having me. This is really becoming a battle over Metzera. Is Metzera worth this much? And who is it worth more to, Novo or Pfizer? Well, I think Metzera is definitely worth this much. As you know, the obesity market is likely to be, in our estimates, upwards of$130 billion when you lump in diabetes. So there is a big opportunity here. And right now, it's only Lillian Novo. So in terms of who it's worth more to, I think Pfizer could make a big splash. They could be a significant third player.

29:31But from the Novo perspective, they need to make up ground. We've seen Novo shares get slashed more than in half at this point because of cutting guidance, as you have said, issues with board, issues with drugs. So they really need something to help them kind of support their next leg of growth. So it's probably worth a lot to both Pfizer and Novo Nordisk, depending on how you look at it. For Pfizer, it really gets them into the obesity space. And for Novo, it sort of plugs their portfolio. But we are in a period, Evan, where next year, the beginning of next year, they're going to be ready to launch their oral Agobi pill pending FDA approval.

30:10The company said on the conference call they've got plenty of supply. They are ready to meet any demand that there is compared to the launch of the shot where they had, you know, too much demand and not enough shots. And so how should we think about the MetSara deal and how should we think about how MetSara complements their portfolio and gets them deeper into it, rounds it out and makes it more competitive against Lilly specifically? Well, so you have Lily's Orphaglipron launching next year, which I think is going to be a very competitive product, which we've talked a lot about. So in terms of what Novo needs, MetSera gives them a longer acting GLP-1, which they don't have.

30:45So instead of once a week, you have it once a month. You have another option for Amlin. So when I spoke to the company today following results, they indicated that they want multiple shots on goal with Amlin with either Cagri, Cagrilatide, Amacretin, and potentially the MetSera asset. And, of course, the Metzera oral is a peptide that does not have the food effect. We've talked a lot about this where we'll go in a pill, you have to not eat for a half hour after you take it. EDS, not to make you play the role of risk arbitrageur, but it seems as though Metzera, given what we're seeing from both these participants, is still relatively undervalued.

31:23Understanding there's risk arb, risk by definition out there. What are your senses about the stock at these levels? I mean, listen, I think that a de-risked obesity asset is hot. And it's pretty clear that this is something that both Pfizer and Novo and a third party that was in the proxy filing wanted. And so I think that there is definitely value that could be unlocked. And I expect the Pfizer bid to potentially best Novo Nordisk. The thing with the Pfizer bid is that if it's accepted, they've already received FTC clearance. So it could close within a number of weeks. I want to switch gears a little bit, Evan, and talk about drug pricing in the administration.

32:03There's a deal that's expected to be announced as early as tomorrow that the lowest dose of the weight loss drugs would be sold on Trump Rx for$149 in exchange, basically, for Medicaid and Medicare coverage of the drugs for the treatment of obesity as opposed to type 2 diabetes, which it's currently covered for. How meaningful is that to these stocks? I think that is very meaningful. That's been kind of the missing piece when it comes to the obesity market, getting real Medicare coverage. You kind of have it backdoor via sleep apnea for some of the indications of ZepBound, for example. So this is definitely meaningful.

32:39And I think the$2.99 price for ZepBound actually is a pretty good deal. It's$50 lower than the lowest dose cash pay with Lilly Direct. So it's not that much of a concession. And I expect the prices for the higher doses to be higher. So net-net, it's a win for Lilly and Novo because they get access to this very large market. You just trimmed your price target for Novo Nordisk. You raised your price target for Eli Lilly. So in your view, that discrepancy in terms of performance, that'll just widen. If the MetSera deal gets done in Novo's favor, Evan, does that change anything? Well, I think it's going to take, if the MetSera deal is the deal that's chosen for, if Novo's chosen as the winner for MetSera, it's probably going to take two years for FTC to clear that.

33:22So it's kind of a state of limbo, allowing Lilly to only move ahead further. You know, I think it's been pretty clear kind of over the past year, Lilly's crushing it fundamentally, right? They raised guidance. They beat numbers. They have Orphaglipron coming. And I feel like they have real focus when it comes to this space where Novo has just been lost. Yeah. And MetSara goes off the board, whether it be Pfizer or Novo. What's the next target in your view? Ooh, that's a tough one. I think outside of the obesity space, a lot of focus on inflammation, inflammatory disease. And of course, in obesity, I cover structured therapeutics.

33:59They have phase two big data coming later this year. We've talked a lot about that on the show. And people do ask me about Viking. I don't cover them, but it could be an interesting move for the right price. Evan, great to see you. Thank you. Evan David Siegerman, EDS of BMO. How do these stocks look, Carter? Particularly Nova, which has been so weak. Well, yes, that's the one. It's just the definition of an uninterrupted downtrend. And it's a testament to momentum, right? Momentum is not just up. It's down. And so it has to be respected. And as tempting as it might be to try to play for a bottom, bottoms have a look and feel.

34:34It takes time and duration. This is just an established downtrend. Stay away. When I look at it, I do try to look for a bottom. And I go back to we're at the 2022 levels right now. So could I be wrong? Of course I could. But this would be a great spot to take a flyer out on it. If you want a more balanced risk, buy Pfizer. Structured GPCR we've talked about. Vikings, another one. Listen, pretty binary, but also given everything that's going on, absolutely I think they can play on the M &A front. You know what you get when you try to pick a bottom. This is the old market saying, and the people should know this joke.

35:09Stinky fingers. So don't. So don't try to pick a bottom. Okay, all right. I don't understand what you mean. I'm trying to boil it down. Just don't chase after this. They'll show you. That's what he's saying. Anyway, coming up, a buy and a sell. Caterpillar and Roku both up solidly this year, but the chart master says they are about to go in different directions. The one he is betting on and the one that's a pair of twos. Fast Money is back in two.

35:43Welcome back to Fast Money. Certainly the chart master has opposing takes on two stocks that have had solid years so far. Shares of Roku, they've quietly doubled off their lows of the year, up more than 40 percent. And take a look at Cat, just off a record high hit last week, up more than 50 percent. So what are you seeing in these two, Carter? Let's get to work. So chart number one, let's start with Roku. Roku is a boom-bust kind of thing. Now, you don't see that here in this first chart, but look at the importance of the 110 level. Let's pull this back a little further and look at the second of three iterations.

36:18That 110 level is in play. Let's look at the third and final chart, which picks up what a boom bust this thing has been. This dropped from 600 to 35, losing about 90 percent of its value, and has been basing ever since. And this action, to my eyes, suggests higher prices. But Caterpillar, a darling, of course, two charts. It is trading at this very moment basically farther above trend, farther above the 150-day moving average than you will typically see at any point in history. This is one duration. Now, let's look at a longer-term duration over the past 10 years. And so, again, just noting where the stock is in relation to where it's been and its average trailing price over 150 days.

37:03But I would also point out that since 1980, Caterpillar has almost four times the performance of the industrial sector and almost three times that of the S &P. So I'm curious, Carter. I mean, there's talk that Caterpillar needs to be re-rated, that there's a different perspective on Caterpillar because of its AI exposure, because of its exposure to alternative energy, particularly solar. And I'm just wondering, you know, in terms of the chart, I guess it doesn't enter anywhere in that. Well, it does. Remember, the chart is the collective judgment of all owners and those who sold today and those who bought more, as well as think about all the bright men and women on Wall Street who are paid as securities analysts to try to get this right.

37:45They are highly designated CFA, CPA, MBA, and they're spending time studying tractors and kamatsu, I guess, as they're at John Deere. And guess, collectively, do you know what the 45 analysts who cover this believe in one year the stock is worth? Their price target is$571, and it closed today at$569. So I guess all those smart people don't think much of it from here. Yeah, it's not in a sexy part of the market, but it's a performer. And when you look at it, though, what would you rather do, Roku or CAT? So Self, would you rather? You are. I'd rather go with Roku. Yeah. Improving profitability, strong ad sales.

38:25and is there going to be more cord cutting or less cord cutting going forward? More. They benefit from that. I think it would be more fun to be in a cat tractor, but I agree with Steve in terms of Roku. And this is a classic bearish to bullish reversal. Valuation makes no sense, but the catch-up trade is going to be fierce. I think Piper just upgraded it to neutral with a$135 price target, and that is not unreasonable given where it's traded historically and given this bottoming formation. What are your thoughts on cat, though, on the run? Well, it is an AI trade now. Yes. Valuation-wise, it's still not that ridiculously expensive.

39:02So, yes. So, despite Carter Braxton worse. No, I like Caterpillar here. I understand. I totally get it. $5.71, the average price target, it is trading there now. But Caterpillar is still relatively cheap, and it is an AI trade. Caterpillar as an AI trade sounds very 2000 to me. I just want to be really clear on that. I mean that sincerely, like, or 99 into 2000. But you want to hear a real AI play? And we talked about a guy had the CEO of BetterOn the other night, right? This AI, you know, mortgage platform. Look at Lemonade today. This is a company, and Daniel Schrober has been on the show. He's been on the show.

39:37This is a company that was billed on AI. Insurance company. The stock was up 35 % on a beaten race. So there's going to be plenty of really good stories. I just don't think it's a tractor company that's a great AI. Well, I'm just saying. They're digging holes. By the way, Tim's seen, not that anybody cares, but Tim has a John Deere tractor. He does. And John Deere also, by the way, is seen as an AI play. Yes, it is. Can you imagine Tim, though, and his John Deere? Good-looking guy in a Deere tractor. I mean, it's fantastic. Has Caterpillar ever said that they themselves think they're an AI play?

40:07Or is that sort of... Let's go to their transcript. Let's go to the tape. Coming up, AI overhaul, how Apple's reportedly getting help to update its Siri voice assistant and how much they're paying for it. More Fast Money in 2.

40:29Welcome back to Fast Money. Google parent Alphabet up 2.5 % today. Apple finalizing a deal to use the company's Gemini AI engine to power its Siri voice assistant. This, according to Bloomberg, Apple would reportedly pay about$1 billion annually to Google. So now we're getting a glimpse of what that new revamped Siri is going to be, which is supposed to be a big catalyst for Apple. Dan? Seems like a great trade. Google pays them$20 billion a year for exclusive search on Safari on iOS devices, and then they're going to pay them a billion dollars a year on a model that they probably spent tens, maybe hundreds of billions of dollars kind of getting ready.

41:03So, I mean, this is great news for Apple. Since the horrible rollout of Apple intelligence, I'm going to go back maybe two, a year and a half ago, they've really been deliberate. And you know what? By the sales of the phone this last couple months, it doesn't seem like investors are, or actually investors are excited, but consumers don't really care that Siri still stocks, so maybe Siri gets better. In the report, it may seem like this is just a stopgap measure until Apple's own model will get up to par with the ones that are on the market right now. But the parameter, I mean, it's a 1.2 trillion power parameter model that Google has.

41:36And Apple's model is 150 billion. I mean, that just shows you the scale and how far behind, if you will, Apple is when it comes to these models. Five years behind, but have they ever really been ahead? If you think about it, that's a game they're playing, and they're not losing to that game, by the way. In the end, Apple might win to waiting and letting everybody else sort of lead the way. I believe that. I think that they're not spending any money on CapEx towards this. They've never been the great innovator. They've been the great replicator. I think that's a positive for Apple going forward.

42:08Quick on the chart, whichever, Google, Apple. I'm sort of a trimmer of both. Oh, okay. Up next, final trades.

42:25Time for the final trade. Steven. Delta. That's my pick. Positive momentum. Positive earnings revisions. Delta. Carter Braxton Worth. Roku. On the man. Making the turn. Buy it. Dan. Yeah. Apple. The story is definitely shaping up. But as Carter just said, I'd be a trimmer of Apple. God. You feel any different today in the wake of your birthday? I noticed I didn't say a number. I feel a cupcake. I could say it. I could say it. Structured therapeutics, Mel. Thank you for watching Fast Money. I could say it. See you tomorrow. Mad Money with Jim Cramer starts right now.

43:07All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:41To view the full Fast Money Disclaimer, please visit CNBC.com forward slash Fast Money Disclaimer.

From the publisher

Earnings are filtering in, and companies are seeing a tale of two very different consumers. The group raising concerns about their customer base, and the names not seeing any slowdown. Plus Novo and Eli Lilly nearing a deal with the White house to lower obesity drug prices. What it means for the space, and how it could change medicare coverage of the weight loss drugs.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Different Reads On The Consumer… And Pharma’s Obesity Drug Price Negotiations 11/5/25CNBC's "Fast Money" · 44 min
Listen in VO